Breast Cancer: Unlocking the Mystery of Treatment Resistance
The battle against cancer has made remarkable strides, but the emergence of drug resistance remains a formidable obstacle. Imagine a scenario where a patient's cancer initially responds to treatment, only to become resistant later, leading to devastating consequences. This is the harsh reality for many patients with metastatic breast cancer, where resistance can develop within two years of starting treatment, causing a significant number of cancer-related deaths in women (O'Leary et al., 2021; Goel et al., 2021).
The root of this resistance lies in the intricate world of cellular processes. In healthy cells, the cell cycle is a tightly regulated process, with the G1 phase acting as a crucial checkpoint before DNA replication. Here, the proteins CDK4 and CDK6 play a pivotal role, controlling cell growth and division by inactivating the retinoblastoma protein (Rb), a tumor suppressor. This inactivation releases E2Fs, transcription factors that kickstart DNA replication and propel the cell into the S phase. As the cell cycle progresses, CDK2 takes over from CDK4/6, ensuring DNA replication occurs smoothly.
But in hormone-driven breast cancer, CDK4 and CDK6 can become overactive, leading to uncontrolled cell division. While drugs that inhibit these enzymes have been developed (Johnston et al., 2020), some tumors find a way to resist by activating CDK2. This revelation suggests that targeting both CDK4/6 and CDK2 might be the key to overcoming resistance.
And this is exactly what a groundbreaking study by Hee Won Yang and colleagues, including Jessica Armand as the lead author, has discovered (Armand et al., 2025). The researchers, affiliated with Columbia University and Emory University, investigated hormone-driven and triple-negative breast cancer cell lines with an intact Rb/E2F pathway. They exposed these cells to CDK4/6 inhibitors for an extended period, inducing drug resistance. But here's where it gets intriguing: after resistance developed, some cells were taken off the treatment, while others continued receiving the inhibitors.
The results were eye-opening. Cells that remained on the treatment grew significantly slower than those taken off, indicating that even resistant cells retain some sensitivity to CDK4/6 inhibitors. Further analysis revealed that these treated cells lingered longer in the G1 phase and divided more slowly. They also exhibited reduced E2F activity and weaker Rb phosphorylation, keeping Rb active and halting cells in the G1 phase. Adding a CDK2 inhibitor enhanced this effect, while overexpressing Cyclin E, which works with CDK2 to force cells into the S phase (Kim et al., 2025), weakened the inhibitor's impact. This suggests that CDK2 plays a crucial role in driving the cell cycle, even when CDK4/6 is compromised.
The implications of this study are profound. It challenges our understanding of drug resistance, suggesting that resistant tumors may still respond to treatment, albeit less effectively than non-resistant tumors. Continuing treatment with CDK4/6 inhibitors, especially in combination with CDK2 inhibitors, could be a promising strategy to slow down cell division. This approach might explain why some clinical trials have observed benefits from prolonged CDK4/6 inhibitor use (Kim et al., 2023).
However, there's a catch. This strategy may not work for all tumors, especially those with mutations in the Rb gene. Additionally, the influence of endocrine therapy on the response to dual inhibition of CDK2 and CDK4/6 remains unclear. To tailor this approach to individual patients, more reliable biomarkers are needed to identify which tumors will respond (Zhang et al., 2023).
In summary, these findings open exciting avenues for research and treatment. They emphasize that even a slight slowdown of the cell cycle can have significant therapeutic benefits, and in the face of drug resistance, delaying progression might be a powerful weapon. But the question remains: how can we optimize this strategy for each patient's unique tumor biology? The quest for personalized medicine continues, and the answers may lie in further exploration of these fascinating cellular mechanisms.
